LLY-283靶向PRMT5抑制头颈部鳞癌增殖和转移的实验研究

doi:10.19439/j.sjos.2022.02.006

上海口腔医学 ›› 2022, Vol. 31 ›› Issue (2): 142-147.doi: 10.19439/j.sjos.2022.02.006

LLY-283靶向PRMT5抑制头颈部鳞癌增殖和转移的实验研究

陈祺¹, 谢非², 季颖颖¹, 魏魁杰^1,*, 任强^1,*

1.复旦大学附属中山医院青浦分院口腔科,上海 201700;
2.上海交通大学附属第九人民医院口腔颌面-头颈肿瘤科,上海交通大学口腔医学院,国家口腔医学中心,国家口腔疾病临床医学研究中心,上海市口腔医学重点实验室,上海 200011

收稿日期:2020-08-20 修回日期:2020-10-09 出版日期:2022-04-25 发布日期:2022-05-16
通讯作者: 任强,E-mail: rqking315@163.com;魏魁杰,E-mail: wkj100310@163.com。^*共同通信作者
作者简介:陈祺（1990-）,男,硕士,医师,E-mail:cqbbm20082019@163.com
基金资助:
上海市青浦区科学技术委员会发展基金项目（QKY2019-07）; 复旦大学附属中山医院青浦分院科研青年项目（QY2020-04）

LLY-283 inhibits proliferation and metastasis of head and neck squamous cell carcinoma by targeting PRMT5

CHEN Qi¹, XIE Fei², JI Ying-ying¹, WEI Kui-jie¹, REN Qiang¹

1. Department of Stomatology, Qingpu Branch of Zhongshan Hospital, Fudan University. Shanghai 201700;
2. Department of Oromaxillofacial Head and Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine; College of Stomatology, Shanghai Jiao Tong University; National Center for Stomatology; National Clinical Research Center for Oral Diseases; Shanghai Key Laboratory of Stomatology. Shanghai 200011, China

Received:2020-08-20 Revised:2020-10-09 Online:2022-04-25 Published:2022-05-16

摘要/Abstract

摘要： 目的： 探讨LLY-283通过蛋白质精氨酸甲基转移酶（protein arginine methyltransferase 5,PRMT5）对头颈部鳞状细胞癌（head and neck squamous cell carcinoma,HNSCC）增殖和转移生物学行为的影响。方法： 通过TCGA数据库、实时荧光定量PCR和免疫印迹实验检测PRMT5在HNSCC组织、细胞系中表达水平;利用慢病毒技术构建PRMT5敲低稳转细胞株,分析PRMT5对HNSCC细胞生物学行为影响,药物杀伤实验观察LLY-283在细胞系中IC50变化;细胞实验和裸鼠移植瘤实验进一步检测LLY-283通过PRMT5对HNSCC生物学作用。结果： PRMT5在HNSCC组织和细胞系中高表达,促进HNSCC增殖和转移能力,降低药物LLY-283的IC₅₀值。LLY-283可通过PRMT5显著降低HNSCC增殖和转移能力、体内裸鼠移植瘤体积和Ki-67表达量。结论： LLY-283可能通过抑制PRMT5和Ki-67表达,降低HNSCC增殖、转移和裸鼠移植瘤形成能力,发挥抗肿瘤作用。

关键词: 头颈部鳞癌, PRMT5, LLY-283, 细胞增殖

Abstract: PURPOSE: To explore the effect of LLY-283 on the biological behavior of Head and neck squamous cell carcinoma(HNSCC) proliferation and metastasis through protein arginine methyltransferase 5(PRMT5). METHODS: TCGA database was used to analyze the expression level of PRMT5 in HNSCC tissues and cell lines by RT-PCR and Western blot. Lentiviral technology was used to construct PRMT5 knockdown stable cell line, and analyze the effect of PRMT5 on the biological behavior of HNSCC. Drug killing experiment was used to observe the IC50 changes of LLY-283 in cell lines. Nude mouse xenograft experiments were further tested to observe the biological effects of LLY-283 on HNSCC through PRMT5. RESULTS: PRMT5 was highly expressed in HNSCC tissues and cell lines, which promoted the proliferation and metastasis of cell lines, and reduced the IC₅₀ value of LLY-283. LLY-283 could significantly reduce the cell proliferation and metastasis, tumor volume and Ki-67 expression in nude mice in vivo of HNSCC through PRMT5. CONCLUSIONS: LLY-283 inhibits the expression of PRMT5 and Ki-67, thereby decreases the proliferation and metastasis of HNSCC and the ability to form transplanted tumors in nude mice, exerting anti-tumor effects.

Key words: Head and neck squamous cell carcinoma, PRMT5, LLY-283, Cell proliferation

中图分类号:

R739.8

陈祺, 谢非, 季颖颖, 魏魁杰, 任强. LLY-283靶向PRMT5抑制头颈部鳞癌增殖和转移的实验研究[J]. 上海口腔医学, 2022, 31(2): 142-147.

CHEN Qi, XIE Fei, JI Ying-ying, WEI Kui-jie, REN Qiang. LLY-283 inhibits proliferation and metastasis of head and neck squamous cell carcinoma by targeting PRMT5[J]. Shanghai Journal of Stomatology, 2022, 31(2): 142-147.

参考文献

[1] Cohen EEW, Bell RB, Bifulco CB, et al.The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)[J]. J Immunother Cancer, 2019, 7(1): 184-215.
[2] Franzen A, Bootz F, Dietrich D.Prognostic and predictive methylation biomarkers in HNSCC: Epigenomic diagnostics for head and neck squamous cell carcinoma (HNSCC)[J]. Hno, 2020, 68(12):911-915.
[3] Zhu K, Song JL, Tao HR, et al.Discovery of new potent protein arginine methyltransferase 5 (PRMT5) inhibitors by assembly of key pharmacophores from known inhibitors[J]. Bioorg Med Chem Lett, 2018, 28(23-24): 3693-3699.
[4] Jing P, Zhao N, Ye M, et al.Protein arginine methyltransferase 5 promotes lung cancer metastasis via the epigenetic regulation of miR-99 family/FGFR3 signaling[J]. Cancer Lett, 2018, 427:38-48.
[5] Zakrzewicz D, Didiasova M, Kruger M, et al.Protein arginine methyltransferase 5 mediates enolase-1 cell surface trafficking in human lung adenocarcinoma cells[J]. Biochim Biophys Acta Mol Basis Dis, 2018, 1864(5 Pt A): 1816-1827.
[6] Ge L, Wang H, Xu X, et al.PRMT5 promotes epithelial-mesenchymal transition via EGFR-β-catenin axis in pancreatic cancer cells[J]. J Cell Mol Med, 2020, 24(2): 1969-1979.
[7] Qin Y, Hu Q, Xu J, et al.PRMT5 enhances tumorigenicity and glycolysis in pancreatic cancer via the FBW7/cMyc axis[J]. Cell Commun Signal, 2019, 17(1): 30-44.
[8] Li YH, Tong KL, Lu JL, et al.PRMT5-TRIM21 interaction regulates the senescence of osteosarcoma cells by targeting the TXNIP/p21 axis[J]. Aging (Albany NY), 2020, 12(3): 2507-2529.
[9] Saloura V, Vougiouklakis T, Sievers C, et al.The role of protein methyltransferases as potential novel therapeutic targets in squamous cell carcinoma of the head and neck[J]. Oral Oncol, 2018, 81: 100-108.
[10] Kumar B, Yadav A, Brown NV, et al.Nuclear PRMT5, cyclin D1 and IL-6 are associated with poor outcome in oropharyngeal squamous cell carcinoma patients and is inversely associated with p16-status[J]. Oncotarget, 2017, 8(9): 14847-14859.
[11] Amano Y, Matsubara D, Yoshimoto T, et al.Expression of protein arginine methyltransferase-5 in oral squamous cell carcinoma and its significance in epithelial-to-mesenchymal transition[J]. Pathol Int, 2018, 68(6): 359-366.
[12] Wang Y, Hu W, Yuan Y.Protein arginine methyltransferase 5 (PRMT5) as an anticancer target and its inhibitor discovery[J]. J Med Chem, 2018, 61(21): 9429-9441.
[13] Lattouf H, Poulard C, Le Romancer M.PRMT5 prognostic value in cancer[J]. Oncotarget, 2019, 10(34): 3151-3153.
[14] Liu F, Xu Y, Lu X, et al.PRMT5-mediated histone arginine methylation antagonizes transcriptional repression by polycomb complex PRC2[J]. Nucleic Acids Res, 2020, 48(6): 2956-2968.
[15] Tan Z, Chen K, Wu W, et al.Overexpression of HOXC10 promotes angiogenesis in human glioma via interaction with PRMT5 and upregulation of VEGFA expression[J]. Theranostics, 2018, 8(18): 5143-5158.
[16] Huang S, Chi Y, Qin Y, et al.CAPG enhances breast cancer metastasis by competing with PRMT5 to modulate STC-1 transcription[J]. Theranostics, 2018, 8(9): 2549-2564.
[17] Liu M, Yao B, Gui T, et al.PRMT5-dependent transcriptional repression of c-Myc target genes promotes gastric cancer progression[J]. Theranostics, 2020, 10(10): 4437-4452.
[18] Chen H, Lorton B, Gupta V, et al.A TGFβ-PRMT5-MEP50 axis regulates cancer cell invasion through histone H3 and H4 arginine methylation coupled transcriptional activation and repression[J]. Oncogene, 2017, 36(3): 373-386.
[19] Chiang K, Zielinska AE, Shaaban AM, et al.PRMT5 is a critical regulator of breast cancer stem cell function via histone methylation and FOXP1 expression[J]. Cell Rep, 2017, 21(12): 3498-3513.
[20] Chiang K, Davies CC.Linking PRMT5 to breast cancer stem cells: new therapeutic opportunities?[J]. Mol Cell Oncol, 2018, 5(3): e1441628.
[21] Zhang S, Ma Y, Hu X, et al.Targeting PRMT5/Akt signalling axis prevents human lung cancer cell growth[J]. J Cell Mol Med, 2019, 23(2): 1333-1342.
[22] Gu Z, Gao S, Zhang F, et al.Protein arginine methyltransferase 5 is essential for growth of lung cancer cells[J]. Biochem J, 2012, 446(2): 235-241.
[23] Stopa N, Krebs J E, Shechter D.The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond[J]. Cell Mol Life Sci, 2015, 72(11): 2041-2059.
[24] Scaglione A, Patzig J, Liang J, et al.PRMT5-mediated regulation of developmental myelination[J]. Nat Commun, 2018, 9(1): 2840-2853.
[25] Liu L, Zhao X, Zhao L, et al.Arginine methylation of SREBP1a via PRMT5 promotes de novo lipogenesis and tumor growth[J]. Cancer Res, 2016, 76(5): 1260-1272.
[26] Wang Z, Kong J, Wu Y, et al.PRMT5 determines the sensitivity to chemotherapeutics by governing stemness in breast cancer[J]. Breast Cancer Res Treat, 2018, 168(2): 531-542.
[27] Bonday ZQ, Cortez GS, Grogan MJ, et al.LLY-283, a potent and selective inhibitor of arginine methyltransferase 5, PRMT5, with antitumor activity[J]. ACS Med Chem Lett, 2018, 9(7): 612-617.
[28] 达雨, 杨震, 夏苗苗, 等. Ki-67、PI3K、Beclin1在口腔鳞癌组织中的表达及意义[J]. 上海口腔医学, 2020, 29(1): 75-79.
[29] 张陈平. 口腔颌面头颈肿瘤诊治的挑战[J]. 口腔颌面外科杂志, 2020, 30(1): 7-10.

LLY-283靶向PRMT5抑制头颈部鳞癌增殖和转移的实验研究

LLY-283 inhibits proliferation and metastasis of head and neck squamous cell carcinoma by targeting PRMT5

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 12

编辑推荐

Metrics

本文评价

[1]	赵开, 张宇宁, 纪帅旗, 刘颖, 姜涵. CFL-1在头颈部鳞癌中的表达与患者预后的关系[J]. 上海口腔医学, 2024, 33(2): 148-155.
[2]	刘文静, 李梦琦, 崔祥, 汪俊兰. circ_0000326靶向miR-567对口腔鳞状细胞癌HSC3细胞增殖、侵袭及迁移的调控效应[J]. 上海口腔医学, 2023, 32(6): 590-596.
[3]	王科, 彭国光, 谭玉莲, 何善志, 罗翠芬. miR-99a对口腔鳞癌增殖能力的影响[J]. 上海口腔医学, 2021, 30(1): 44-49.
[4]	郑晶, 李天客, 包阳, 张素欣. Spindly和Bub3在口腔鳞状细胞癌中的表达及意义[J]. 上海口腔医学, 2020, 29(5): 528-532.
[5]	曹颖, 彭伟伟, 王璇, 伍甜甜, 杜嵘, 朱亚琴. 重组人结缔组织生长因子对牙髓细胞增殖与成牙本质分化的影响[J]. 上海口腔医学, 2020, 29(1): 7-12.
[6]	冯小东, 易文, 殷卫红. 过表达miR-218对舌鳞癌细胞系SCC-4和SCC-9的增殖和侵袭的影响[J]. 上海口腔医学, 2019, 28(4): 373-377.
[7]	张漫, 李昊, 徐婷, 刘杰, 谈飞. 含锶交联藻酸钠凝胶对前成骨细胞黏附和增殖的影响[J]. 上海口腔医学, 2019, 28(2): 123-127.
[8]	高锦瑜, 余小琴, 王军强. 周期性牵张应力作用下KLF5对人牙周膜细胞增殖和成骨分化的影响[J]. 上海口腔医学, 2018, 27(1): 28-33.
[9]	李凤霞, 王俊, 马玉云. CCN3调控牙周膜成纤维细胞的增殖和凋亡[J]. 上海口腔医学, 2017, 26(5): 504-509.
[10]	刘秉尧, 曹罡, 董震, 陈伟, 徐金科, 张森林, 翁志强. 沉默Grb7对口腔鳞癌细胞Cal27生物学行为的影响[J]. 上海口腔医学, 2016, 25(6): 688-693.
[11]	张平平, 徐秀英, 高振南. 低糖基化E-cadherins对舌鳞癌细胞增殖和侵袭的影响[J]. 上海口腔医学, 2014, 23(1): 1-6.
[12]	丁进, 尹元正. 血管内皮细胞对牙周组织细胞增殖的影响[J]. 上海口腔医学, 2013, 22(5): 518-522.